Is Johnson & Johnson's Dividend Unbeatable?

Before you go, we thought you'd like these...
Before you go close icon

Major health-care stocks out of big pharma and medical devices offer great dividends, but few offer the strength and reliability of sector colossus Johnson & Johnson . While it may not boast the highest yield in health care at only 2.7%, the firm's inclusion among the S&P 500's Dividend Aristocrats -- companies that have raised their dividend in each of at least the past 25 years -- along with its diversity across consumer, medical device, and pharmaceutical units makes Johnson & Johnson's dividend a contender among the best in the market in the long term.

Yet that's not all this powerhouse stock has going for it. J&J's outperformed the S&P 500 year to date, with its stock gaining 9% in 2014 despite the market's sluggishness. The company's just off of a strong first-quarter earnings report that posted an 8% year-over-year growth in profit, and its pharmaceutical division has ignited recently, with sales in the unit up 11% for the quarter.

With the security of its diversity and the recent growth in drug sales, can investors find a better dividend in health care than Johnson & Johnson? In the video below, Motley Fool contributor Dan Carroll takes you through what you need to know about this powerhouse dividend and how J&J's success can help your portfolio thrive.

Is Johnson & Johnson among the best dividend stocks for the next decade?
The smartest investors know that dividend stocks like Johnson & Johnson simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now. 

The article Is Johnson & Johnson's Dividend Unbeatable? originally appeared on

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading